Purpose: We sought to determine whether women with overactive bladder who required third line therapy would demonstrate greater central sensitization, indexed by temporal summation to heat pain stimuli, than those with overactive bladder. Materials and Methods: We recruited 39 women with overactive bladder from the urology clinic who were planning to undergo interventional therapy for medication refractory overactive bladder with onabotulinumtoxinA bladder injection or sacral neuromodulation. We also recruited 55 women with overactive bladder who were newly seen at our urology clinic or who responded to advertisements for study participation. Participants underwent quantitative sensory testing using a thermal temporal summation protocol. The primary study outcome was the degree of temporal summation as reflected in the magnitude of positive slope of the line fit to the series of 10 stimuli at a 49C target temperature. We compared the degree of temporal summation between the study groups using linear regression. Results: Women in the group undergoing third line therapy showed significantly higher standardized temporal summation slopes than those in the nontreatment group (b ¼ 1.57, 95% CI 0.18e2.96, t ¼ 2.25, p ¼ 0.027). On exploratory analyses a history of incontinence surgery or hysterectomy was associated with significantly greater temporal summation. Conclusions: In this study the degree of temporal summation was elevated in women undergoing third line overactive bladder therapy compared to women with overactive bladder who were not undergoing that therapy. These findings suggest there may be pathophysiological differences, specifically in afferent nerve function and processing, in some women with overactive bladder.
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* normal or abnormal stimuli may contribute to the development of or exacerbate existing OAB. We have postulated that CS, a phenomenon well described in the chronic pain literature in which afferent C fiber circuits display hyperresponsiveness, 3 may have such a role in certain individuals with OAB. 1 We previously reported that compared to women without OAB those with OAB who required third line therapy with onabotulinumtoxinA bladder injection or sacral neuromodulation showed greater thermal cutaneous TS, that is increasing perceived pain in response to rapid repetition of the same stimulus intensity. 4 Because elevated TS is believed to be a marker for CS, 5, 6 this finding suggested elevated CS in patients with OAB when compared to nonOAB controls.
Our current hypothesis was that CS may contribute to why some women with OAB are more likely than others to be refractory to first and second line OAB therapy. As the next step in this line of investigation, the aim of the current study was to determine whether women with OAB undergoing third line therapy would show greater TS than women with OAB not undergoing these treatments.
MATERIALS AND METHODS
After obtaining institutional review board approval we recruited 39 women 18 years old or older with OAB from the urology clinic who were planning to undergo onabotulinumtoxinA bladder injection or sacral neuromodulation. We also recruited 55 women with OAB, which was confirmed by a score of 4 or greater on the OAB-V3 (OAB-Version 3) awareness tool, 7 who were newly seen at our urology clinic or who responded to community advertisements and were not undergoing third line therapy.
We excluded women from analysis if they were diagnosed with a neurological condition that might contribute to urinary symptoms (eg spinal cord injury, multiple sclerosis, stroke or autonomic dysfunction), had a history of bladder cancer, pelvic irradiation or bowel diversion, or were unable or unwilling to complete all study protocols. We also excluded women with interstitial cystitis/bladder pain syndrome based on medical record review and/or whether they met the RICE (Rand Interstitial Cystitis Epidemiology) case definition. 8 Participants completed a standardized questionnaire assessing demographics and medical history, including age, race/ethnicity, highest education level, general health, prior history of incontinence surgery, hysterectomy or prolapse surgery and whether they were receiving OAB medications. We assessed pelvic surgical history with yes or no questions, that is, "Have you ever had.?" a hysterectomy, an operation to remove the uterus or womb, or surgery for incontinence (urine leakage) or to repair pelvic organ prolapse (pelvic floor disorder, cystocele or rectocele).
Participants also completed the OAB-q 9 and the ICIQ-FLUTS. 10 To assess psychosocial and somatic characteristics they completed the NIH (National Institutes of Health) PROMIS short form, version 1.0 instruments for depression (8a), anxiety (8a) and pain intensity (3a) as well as the SSS-8 (Somatic Symptom Scale-8). 11 We also assessed the presence of comorbid functional somatic conditions by self-report (ie low back pain) or by validated patient reported diagnostic measures, including migraine headache, 12 fibromyalgia 13 and irritable bowel syndrome. 14 
Quantitative Sensory Testing
All quantitative sensory testing protocols were done using a TSAII NeuroSensory Analyzer (Medoc, Minneapolis, Minnesota) with a 9 cm 2 Peltier thermode applied to the volar forearm. To determine heat pain threshold and tolerance levels we performed a series of 4 pain trials during which the probe temperature increased from a baseline temperature of 32C at a rate of 0.5C per second. In the heat pain threshold test the participant indicated the temperature at which the heat was first perceived as painful. In the heat pain tolerance trials the participant indicated when the pain became intolerable. We then separately derived the means of the 4 threshold and tolerance trials.
Our quantitative sensory techniques to measure TS are similar to those that are standard in the pain literature. 6, 15 They were previously detailed in the context of OAB. 4 Briefly, we administered a sequence of 10 successive 0.5-second heat pulses to the forearm, during which the temperature rapidly increased and decreased from a temperature of 40C to 49C at a frequency of 0.4 Hz. This frequency is known to elicit C fiber mediated temporal summation in the dorsal horn of the spinal cord. Immediately after the peak of every heat pulse the subjects provided a verbal numerical pain intensity rating using a VAS on a scale of 0dno pain or warmth to 100dworst possible pain. The standardized slope of the change in pain ratings over the series of 10 stimuli was derived for each patient as a TS index. A positive slope (greater than 0) indicated the presence of TS while a negative slope (less than 0) indicated habituation.
Statistical Analyses
Statistical analyses were performed with Stata/SEÔ 14.1. We used the Student t-test to compare continuous variables and the chi-square test for categorical variables. Our independent variable in all primary analyses was the OAB group (OAB vs OAB undergoing third line therapy). We created linear regression models with the pain response index as the dependent variable (ie pain threshold, tolerance or TS), the OAB group as the independent variable, and patient age and the OAB-q score as control variables. To analyze TS we also included the initial VAS pain rating of the first TS stimulus to control for confounding due to baseline effects on observed slopes (ie ceiling effects). Finally, we explored possible factors that may have been associated with the observed degree of TS using linear regression models in which the TS slope was the dependent variable. Analyses were done with 2-tailed p <0.05 considered statistically significant.
RESULTS

Participant Characteristics
Study participants who were undergoing third line OAB therapy were older and slightly less educated, and reported less general good health but they did not differ by race/ethnicity (table 1). More women in the third line therapy group had undergone prior pelvic surgery, although specific details on these procedures were not available, and significantly more were taking OAB medications. Urinary symptoms were more severe in the third line therapy group, as reflected in higher mean OAB-q symptom scores, total ICIQ-FLUTS scores and ICIQ urge incontinence scores. This group also reported lower mean OAB-q quality of life scores (table 2) .
Heat Pain Threshold and Tolerance
Mean thermal pain threshold and tolerance temperatures were similar between women who were vs were not receiving third line OAB therapy, including 44.0 (95% CI 43.2e44.8) vs 44.3 (95% CI 43.2e45.4) and 47.4 (95% CI 46.9e47.8) vs 47.3 (95% CI 46.8e47.8), respectively. After adjustment for age and OAB-q symptom scores neither pain threshold nor pain tolerance levels differed between the 2 groups (data not shown, each p >0.10).
Temporal Summation
During the TS protocol the mean VAS pain intensity ratings in response to application of the first heat pain stimulus were similar in the OAB and third line therapy groups (35.8, 95% CI 27.9e43.6 and 39.3, 95% CI 31.0e47.5, respectively). In the OAB group 4 women (7%) showed negative slopes, 4 (7%) showed no change in pain ratings and 47 (86%) showed positive slopes (range 0.1-9.4). In the third line therapy group 4 women (10%) showed negative slopes, 1 (3%) showed no change and 34 (87%) showed positive slopes (range 0.1-13.0).
The unadjusted mean AE SD of standardized TS slopes was significantly greater in the third line treatment group than in the OAB only group (3.5 AE 3.8 vs 2.2 AE 2.4, t ¼ e2.11, df ¼ 92, p ¼ 0.037). Even after we controlled for group differences in age, OAB-q scores and initial VAS pain intensity rating in our linear regression model this difference in TS slopes between the groups was preserved (b ¼ 1.57, 95% CI 0.18e2.96, t ¼ 2.25, p ¼ 0.027, see figure) .
Exploratory Analyses
We examined several factors that may have been associated with elevated TS across the 2 treatment groups (table 3) . In these analyses we excluded 8 participants with a negative slope, which by definition did not indicate TS. In addition, because of the recognized potential for ceiling effects on TS slopes due to higher initial VAS pain ratings in some individuals and potential confounding due to age, we adjusted for these variables in the analyses.
Symptom severity as an aggregate score (eg the OAB-q symptom score) or as individual symptoms (eg urgency, urge incontinence, etc), was in general not associated with the degree of TS except for a positive association between TS and bladder pain (b ¼ 0.78, 95% CI 0.02e1.54). The PROMIS anxiety scores (b ¼ 0.09, 95% CI 0.02e0.16) were also associated with increased TS while scores on somatic symptom 
DISCUSSION
In this study of women with OAB we documented increased TS levels to heat stimuli in a group of women in whom first and second line therapies failed and who elected third line OAB therapy. Because elevated TS is an indicator of increased CS, this finding suggests that some women who undergo advanced therapy for OAB may have a component of CS that contributes to the pathophysiology/nature of the bladder dysfunction. On an individual level further investigation is needed to identify particular characteristics that may be associated with this finding of elevated TS.
We previously postulated that CS may have a role in the pathophysiology of OAB in some women, although OAB is generally not associated with pain. 1 CS is an induced state of spinal hypersensitivity and a well recognized mechanism of centrally amplified pain perception which facilitates afferent signaling. Repeat activation of afferent C fibers results in conditioning of second-order neurons in the dorsal horn of the spinal cord, which then amplify afferent signals from low threshold Ab and Ad mechanoreceptors, and nociceptive C fibers. 3 Hypersensitive spinal neurons demonstrate reduced firing thresholds, increased receptive field sizes, persistent stimulus independent activity and greater evoked responses. 16 In this context of CS stimuli that generally do not provoke pain can produce pain (ie allodynia) and stimuli that normally provoke pain can produce pain at higher intensity (ie hyperalgesia). Sensory sensitivity can also be increased even without pain (ie hyperesthesia).
Changes related to CS such as those described may parallel to some degree the mechanisms proposed for OAB pathophysiology.
2,17,18 OAB pathophysiology is thought to involve afferent nervous system dysfunction, which is reflected in abnormally increased afferent signals from the bladder and/or decreased capacity to handle afferent signals in the central nervous system. 2 Hypersensitive spinal neurons in patients with OAB, like those in CS, could amplify bladder afferent signals even from low threshold or sub-threshold mechanoreceptors like those involved in normal bladder homeostasis, resulting in increased bladder sensitivity. 18 The perception of pain typically used to describe the effects of CS in chronic pain disorders (ie allodynia and hyperalgesia) may not be specifically relevant to
Comparison of means of temporal summation slopes between women with OAB undergoing vs not undergoing third line therapy. Bar represents mean adjusted for age OAB symptom severity and initial VAS pain scores during temporal summation protocol. Whisker represents SD. the bladder in OAB cases. However, the afferent sensitivity inherent to CS may be relevant for the nonpainful bladder sensations (ie hyperesthesia) that are the hallmark of OAB. The exploratory findings of possible links between pelvic surgery and elevated levels of TS are mechanistically intriguing, although preliminary. As noted CS is believed to develop in response to sustained C fiber input, typically associated with tissue injury and pain. 3 We speculate that pelvic surgery, and the local tissue trauma and pain associated with such surgery might be the trigger eliciting the initial development of CS in some patients. After it develops, this CS could enhance responsiveness to nonpainful bladder stimuli and thereby contribute to OAB symptomatology which is more resistant to first and second line treatments. Determining whether this hypothesis is correct requires replication and additional investigation of these issues. Unfortunately the lack of detailed information on the specific characteristics of prior pelvic surgeries made it difficult to fully interpret these findings in the current work.
An important finding in this study is that while we found differences in TS between women with OAB and women planning to undergo third line OAB therapy, we did not find any difference in thermal pain threshold or tolerance. The TS protocol used in this study was intended to be relatively specific to CS while this is not the case for the protocols used to assess pain threshold or tolerance. Thus, our findings suggest a specific difference in CS rather than a difference in global pain responsiveness.
Since we evaluated TS, pain threshold and pain tolerance in the forearm, a question can be raised regarding whether the forearm would be expected to be sensitive to afferent changes affecting the bladder. Because CS represents an alteration in centrally mediated afferent processing, it is by definition centralized and should influence ascending afferent input from multiple dermatomes. Its effect should be observed in multiple body areas and not just at the level of clinical symptoms, which in this case was the bladder. Applying the stimuli at a dermatome (ie the forearm) spatially removed from that of the bladder (ie the suprapubic area) follows a widely used and validated approach that has successfully demonstrated elevated TS in various chronic pain conditions relative to controls when tested well outside of the location of the clinical pain. 19 However, further study is needed to examine the impact of segmental changes in afferent processing in women with OAB.
Considering limitations to our study, while the sample size was adequate to detect group differences, larger numbers of patients are needed to better phenotype women with OAB and clarify determinants of CS. Also, our study was crosssectional so that we were unable to determine the causal relationship between OAB symptoms and elevated TS, such as whether CS that appears related to OAB reflects a preexisting condition possibly related to some prior bladder or pelvic insult. Lastly, we focused on TS and to a lesser extent on hyperalgesia using thermal pain stimulation. To our knowledge it is unknown whether other stimulus modalities, including mechanical pain stimuli or psychophysical laboratory tests capturing other aspects of pain modulatory processes such as conditioned pain modulation, would demonstrate findings consistent with ours.
CONCLUSIONS
In this study the degree of TS was elevated in women undergoing third line OAB therapy compared to women with OAB not undergoing those treatments. As there are no established objective markers that identify individuals with OAB or pathophysiological mechanisms which may underlie OAB symptoms, our findings that some women with OAB demonstrate CS may represent an important preliminary step toward advancing the care of women with OAB. Future studies need to address whether TS can identify patients early in the OAB disease process, specifically those who may not respond adequately to noninvasive treatment options and may need third line therapy.
